【活動分享】波士頓台灣人生技協會(BTBA)將於台灣時間1/27早上十點舉辦台灣教授於
生醫領域創業的線上座談。此活動邀請到台大化學系徐丞志與北醫生藥所莊國祥教授，他
們同時目前也是各自公司的CEO，並分別榮獲2023十大Best Bio Startup CEOs與環球生技
台灣CEO首獎。兩位教授將分享創業與經營公司的經驗，包含如何開始創業的第一步、營
運公司與實驗室有何不同、對目前台灣創業環境的看法等。歡迎有興趣者報名參加並轉發
分享！
活動詳細資訊：https://www.facebook.com/events/398146829541203/
報名網址：https://forms.gle/AuxUhaW1q7wusrRW8
▶講者 Speakers:
Kuo-Hsiang Chuang Ph.D. (莊國祥)
Dr. Chuang is a professor at Taipei Medical University (台北醫學大學) and the
CEO/founder of CytoArm Co., Ltd (賽昂生醫). Dr. Chuang completed his Ph.D. at
Kaohsiung Medical University in 2010 with more than 20-year experience in
multifunctional antibody drugs, novel tumor-specific T-cell technology
platforms, novel protein drugs for the treatment of autoimmune diseases, and
a variety of tandem repeated protein technologies that can be applied to
enhance the sensitivity of immunoassay technology.
The company CytoArm, developed by Dr. Chuang, is a rising startup biotech
specializing in next-generation T-cell therapy. The patented technology, the
Armed-T cell platform, is ready to initiate a clinical trial for end-stage
untreatable metastatic colorectal cancer. More information can be found at
https://www.cytoarm.com/
Cheng-Chih Hsu Ph.D. (徐丞志)
Dr. Hsu is an associate professor in the Chemistry department at National
Taiwan University (台灣大學) and the founder/CEO of Leeuwenhoek Laboratories
Co. Ltd (雷文虎克生技). He received his Ph.D. at the University of California
San Diego and was trained as a postdoctoral fellow at Stanford University.
His research is focused on using mass spectrometry to explore the chemistry
of complex biological systems and clinical applications, especially human
microbiota. He was selected as one of the “Top 40 Under 40” by the
Analytical Scientist in 2018 and rewarded with the MOST Young Scholar
Fellowship – Columbus Program (哥倫布計畫) in 2019.
Leeuwenhoek Laboratories Co. Ltd is a spin-off from National Taiwan
University. Since August 2021, it has set up three major laboratories:
Metabolomics, Culturomics, and BioMedicine. Leeuwenhoek Laboratories aim to
develop next-generation probiotic therapy by utilizing advanced
bio-technologies such as mass spectrometry analysis and relevant techniques
in intestinal microbiota. More information can be found at
https://www.lwhklab.com.tw
▶活動負責人 Organizers:
Wei-Chao Huang, Ph.D. (黃威超)
Wei-Chao is currently working as a postdoctoral associate at the Broad
Institute of MIT and Harvard. He holds an M.S. in Neuroscience from NYMU in
Taiwan and a Ph.D. in Neurobiology from the University of Utah. During his
Ph.D. studies, Wei-Chao worked on many projects that used next-generation
sequencing to determine the epigenetic mechanisms and allele-specific
expression effects. Furthermore, he and lab members built a startup team with
the Lassonde Entrepreneur Institute to put the research findings into
practice. In 2019, he relocated to Boston to work at Amgen. Presently, he is
studying the mechanisms of neuropsychiatric disorders through mouse models at
the Broad Institute.
LinkedIn: https://www.linkedin.com/in/wei-chao-huang/
Yi-En Liao Ph.D. (廖怡恩)
Yi-En is a Novartis clinical science and innovation fellow in Boston, working
on early-phase clinical trial development and operation. She moved to the
U.S. for an M.S. and a Ph.D. in Pharmaceutical Science at the University of
Southern California and the University of North Carolina at Chapel Hill,
respectively, after her pharmacist training at Taipei Medical University in
Taiwan. During Yi-En’s academic training, her research focused on the
development of anti-inflammatory treatments for inflammatory diseases,
including traumatic brain injury, sepsis, and acute liver injury.
LinkedIn: https://www.linkedin.com/in/yien-liao/
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 111.254.155.81 (臺灣)
※ 文章網址: https://www.ptt.cc/bbs/Bioindustry/M.1704601459.A.5D7.html
※ 編輯: chaowilliam (111.254.155.81 臺灣), 01/07/2024 14:25:46
※ 編輯: chaowilliam (211.22.119.247 臺灣), 01/08/2024 22:07:09